NICE has published guidance on pharmacological interventions for weight management, including NICE guideline CG189 (Obesity: identification, assessment and management) and a technology appraisal supporting the use of semaglutide (Wegovy) for adults with a BMI of 35 kg/m or above (or 3034.9 kg/m in certain circumstances) alongside a specialist weight management service
Label every reconstituted vial with reconstitution date, concentration in mg/mL, and 28-day expiration date
This is fascinating and it brings it back to this question that we had before, and I appreciate that you've answered it very clearly
Pharmacological inhibition of mammalian target of rapamycin attenuates deoxycorticosterone acetate saltinduced hypertension and related pathophysiology: regulation of oxidative stress, inflammation, and cardiovascular hypertrophy in male rats
B.Fink-JensenA.WortweinG.SeeleyR
Almassi GH, Wagner TH, Carr B, Hattler B, Collins JF, Quin JA, et al